The prevalence of benign prostatic hypertrophy (BPH) causing bothersome lower urinary tract symptoms increases with our ageing population. Treatment of BPH traditionally begins with medical therapy and surgical intervention is then considered for those whose symptoms progress despite treatment. Minimally invasive surgical therapies have been developed as an intermediary in the treatment of BPH with the aim of decreasing the invasiveness of interventions. These therapies also aim to reduce morbidity and dysfunction related to invasive surgical procedures.
Introduction
Benign prostatic hypertrophy (BPH) causing bothersome lower urinary tract symptoms (LUTS) becomes more common in men with advancing age, presenting a growing issue in our ageing population. Lifelong hormonal exposure to androgens is thought to cause an ongoing growth response in the prostatic glandular tissue leading to compression of the prostatic urethra with bladder outlet obstruction and LUTS. The management of men with bothersome LUTS may be initiated with conservative measures or medical therapies. 1 Despite this, many patients have symptomatic progression that are refractory to these therapies and that necessitates surgical intervention. Invasive surgical therapies such as transurethral resection of the prostate (TURP) and simple prostatectomy are the current gold standard surgical interventions for BPH. However, these invasive procedures are also associated with considerable peri-operative morbidity. 2 Further, risks to continence and erectile function limit its widespread use. As such, a range of minimally invasive surgical therapies (MIST) have been developed aimed at achieving amelioration of a patient's LUTS and avoiding the risk of adverse outcomes associated with more invasive measures.
Since its introduction, data from the USA identified an increasing proportion of MIST performed annually with a decrease in the rates of TURP. 3 Considering that over this time period, procedures for BPH have risen overall, the epidemiology of MIST procedures is one of rapid expansion. The American Urological Association has incorporated a handful of these therapies into their guidelines for BPH management based on heterogeneous study outcomes, 4 whereas the National Institute for Health and Care
Excellence Guidelines do not recommend their use over TURP for men with voiding LUTS secondary to BPH. 5 The improved morbidity and complication profiles associated with MIST are countered by their higher rate of clinical failure requiring secondary intervention and less dramatic improvement to LUTS and urine flow rates. While these therapies are well tolerated and able to be used in higher-risk surgical candidates, validation of their utility and durability of effect is an ongoing process. We aimed to provide an objective, updated review of the literature regarding various established and emerging MIST options. We aimed to assess the evidence base for the efficacy and safety of varieties of MIST and their appropriate use in patients with BPH.
Transurethral incision of the prostate
Transurethral incision of the prostate (TUIP) intends to produce improvements in urinary function by following similar methods to TURP. However, during TUIP, debulking of the prostate adenoma is not performed. Instead, either an electrocautery device or laser 6 is used to incise the prostate tissue from the bladder neck down to the verumontanum. This incision allows the crowded circumferential band of hypertrophied tissue to separate and the bladder outlet is "opened up." TUIP is typically recommended for men with smaller prostatic glands (<30 cc). The presence of a large median lobe is a relative contra-indication as this may cause ongoing blockage if incised. Bilateral TUIP may be performed but with greater risk of ejaculatory dysfunction compared with a single midline incision. TUIP gives superior outcomes for ejaculatory function when compared with TURP. 7 Outcomes relating to International Prostate Symptom Score (IPSS) have been shown to be similar between TUIP and TURP but with decreased improvement in peak flow rates. 8 
Thermo-ablative strategies
Thermo-ablative strategies in the treatment of BPH rely on the generation and conductance of thermal energies into the prostatic tissues to induce a coagulative necrosis and ultimately tissue destruction. Their respective safety and limited morbidity compared to TURP have been demonstrated. However, like alternate MIST options, these factors are counteracted by their reduced impact on IPSS and patient function, as limited durability of symptomatic improvement exists. Therapies utilizing laser energy for destruction of prostate tissue such as Holmium laser or "greenlight" photoselective vaporization of the prostate are considered as invasive measures. However, these may be used to facilitate the process of some MIST options as seen in TUIP.
Transurethral microwave therapy
Transurethral microwave therapy (TUMT) utilizes microwave radiation heat generation to produce coagulative necrosis in prostatic tissue. This microwave radiation is distributed via an intraurethral antenna which, when correctly placed, can deliver heat to targeted regions of the prostate. TUMT has been shown to improve symptoms and sustain this effect but remains inferior to TURP in its efficacy. Specifically, recent literature reports improvements in IPSS at 12-months follow-up of 65% and 77% after TUMT and TURP, respectively. 9 Similarly, urinary flow rates following TUMT provided a 70% increase and TURP provided a 119% increase. 9, 10 Despite these promising similarities in urinary outcomes, the durability of TUMT is under question due to the high proportions of patients requiring retreatment. Thalmann et al 9 provided a robust analysis of 200 patients who had received TUMT with minimum 2 years' follow-up. In their cohort, 22% of patients required retreatment with either repeat TUMT, TURP, or suprapubic catheterization. Nevertheless, the benefits of TUMT are diverse and include improved sexual function, less hospitalization, decreased hematuria, and lowered requirement for transfusion when compared with more invasive measures. 11 Of these, sexual function outcomes of TUMT are promising with reports of an incidence of retrograde ejaculation of 21.2% on pooled analysis. 7 Being performed under local anesthesia, TUMT has also displayed its usefulness in cohorts of patients who are frail or unsuitable for surgery. 12 
Transurethral evaporization of the prostate
Transurethral electrovaporization of the prostate (TUVP) is a similar MIST that utilizes heat from monopolar or bipolar highvoltage electrical current, resulting in tissue ablation. 13 TUVP has demonstrated symptomatic benefits comparable to conventional TURP. With use, TUVP affords significant reductions in IPSS and improvements in peak urine flow rate of approximately 10 mL/s; however, results were not so promising for a reduction in postoperative morbidity or shorter hospital stay.
14 A recent randomized control study comparing bipolar TUVP to monopolar TURP found that both were effective in reducing patient's IPSS (49.7% and 70.6% at 6 months' follow-up for TUVP and TURP, respectively) and improving peak flow rates, but with more statistically significant results in the TURP group. 15 Use of TUVP was also found to lead to a decreased duration of catheterization, improvements to postprocedure hematuria risk, decreased hematocrit drop, and fewer perioperative complications, but had higher rates of secondary intervention for clinical failure. 16 The relatively recent development of continuous energy bipolar TUVP has displayed benefits when compared with conventional TUVP and monopolar TURP. These mainly relate to decreased operating time, lowered rates of postoperative hematuria, and length of catheterization period but also showed a decrease in perioperative complication rates. 16 
Transurethral needle ablation
Transurethral needle ablation of the prostate is achieved by the placement of two electrodes into the target prostatic tissue and the creation of a radiofrequency signal between them. This results in thermal energy creation and ablation of tissues through coagulative necrosis.
Several randomized trials have been performed with only shortto-midterm follow-up available to date. As with other forms of MIST, concerns regarding durability are present. A 5-year follow-up demonstrated that 58% of patients had maintained symptom control; however, 21% needed retreatment.
14 Meta-analytical data confirms an improved IPSS and urinary flow rate at 1 year; however, to a significantly lower magnitude when compared with TURP. 17 Similar to TUMT and TUVT, transurethral needle ablation has a favorable morbidity profile when compared with TURP. 19 published results of a blinded study where patients underwent a sham procedure then PUL 3 months later to assess the effectiveness of the PUL on IPSS, peak urine flow rates, at 24-months post-PUL. Their findings were consistent with previous studies, 18, 20, 21 with IPSS scores decreasing by 9.6 points at 24 months, and peak urine flow rates increasing by 4.2 mL/s when compared with presham baseline. Sexual function and ejaculatory function were preserved in each of these studies, which may be an important consideration for patients being treated for their LUTS. Longer term follow-up for robust durability data is currently being collated. 
Intraprostatic stents
With use of intraprostatic stenting, the transurethral approach is utilized to identify the point of maximal obstruction and a stent or coil is positioned under endoscopic vision. A variety of stent types are available ranging from temporary biodegradable options to permanent stents. Yildiz et al 23 have reported on 1-year followup data from 51 patients using the Allium Triangular Prostatic Stent (Allium Medical Solutions, Caesarea Industrial Park South, Israel). At 12-month follow-up; patients in this group experienced a mean decrease in IPSS scores from 26.4 to 7.7 and an average increase in peak urine flow rates from 5.5 mL/s to 16.0 mL/s. Two patients required removal of the stent due to significant complications (Clavien Grade 3). The most common reported complication was stent-related pain; however, this was intermittent and no patient required removal of the stent secondary to pain issues.23 Despite the short-term improvement to symptoms, prostatic stents are characterized with potentially significant morbidity including stent migration and recurrent infection. Relatively higher complication rates associated with their use limit their utility as a long-term durable option in BPH management. Further large-scale studies are required to definitively establish the efficacy of these stents. Transurethral ethanol ablation of the prostate is one such method involving injection of pure ethanol. The largest cohort of patients reported in a multicenter, prospective trial showed improvement of both IPSS and quality of life scores (reduced by more than 50%) and improvement to peak flow by 36% at 3-months' postprocedure. These results were sustained to 1-year postprocedure. 27 A separate study with a 4-yr follow-up period suggested a sustained response in 73% of patients with the remaining 23% requiring retreatment. 28 There is a need for further evaluation with comparative data to further quantify the value of transurethral ethanol ablation of the prostate. Agents that induce cellular apoptosis include NX-1207 (Nymox Pharmaceutical Corp, Hasbrouck Heights, NJ, USA) and PRX-302 (Sophiris Bio Corp, La Jolla, CA, USA) and have been designed for minimally invasive injections. NX-1207 has been shown to be safe for use in BPH with sustained reductions in symptom scores over long-term follow-up. 29 In this phase II trial, over half of the NX-1207 treated participants reported no further surgical intervention or medication requirements for their BPH. 29 Further phase II and III trials are underway to confirm the validity of these promising findings. Despite this, NX-1207 remains as experimental. PRX302 is a compound, designed to promote apoptotic activity specifically in native prostate tissue. This protoxin has been altered to include a prostate-specific antigen selective sequence that activates following interaction with active prostate-specific antigen within the prostatic tissue. Initial studies investigating the safety and efficacy of PRX-302 revealed some benefit to symptoms scores and peak flow at the 12-month follow-up. 30 These findings were corroborated in a larger double blind, randomized control trial which found statistically significant improvement to IPSS after 90 days with some reduction of effect at 12 months.
31
Botulinum neurotoxin-A (BoNT-A) is thought to modulate neurotransmitter activity at the neuromuscular junction. It has been utilized in other functional aspects of urology such as overactive bladder and proven safe for clinical use. Use of BoNT-A for BPH LUTS in clinical trials has shown a mixed pattern of results. Urodynamic effects investigated by de Kort et al 32 showed benefit to postvoid residual volumes and symptom scores but no effect on urodynamic outcomes including peak flow. Two randomized controlled studies have been performed to investigate BoNT-A with heterogenous results. Maria et al 33 displayed improvement to postvoid residual volumes by 60% (P < 0.0001) and increased peak flow rates from 8.1 mL/s to 14.9 mL/s (P ¼ 0.00006), which were sustained to the 12-month follow-up. Conversely, a study by Marberger et al 34 with the largest cohort of men treated with BoNT-A, reported nonsignificant improvements in both the control and treatment groups. Indeed, the role of BoNT-A in the treatment of LUTS is yet to be determined and requires further investigation. The National Institute for Health and Care Excellence guidelines suggest that treatment with BoNT-A only occur as part of a randomized control trial. mean Qmax increased from 8.6 mL/s to 18.6 mL/s, mean PVR decreased from 91 mL/s to 30 mL/s. and mean quality of life score decreased from 5.0 to 2.5. Currently, phase III clinical trials are underway comparing Aquablation to TURP, the current gold standard for treatment of BPH. 36 
Prostatic artery embolization
Prostatic artery embolization (PAE) is a procedure performed under radiological guidance and involves highly selective injection into the prostatic arteries. Either unilateral or bilateral prostatic artery injection is performed with an embolic agent, most commonly which is typically nonspherical, polyvinyl alcohol based. Contemporary literature highlights considerable failure rates as high as 19% 37 with 15% of patients requiring TURP within the 1 st year after treatment. Uptake may have been limited due to these factors and availability of specialist interventional radiologists required to perform the procedure. However, increasing experience with PAE has led to improved procedural success rates. PAE has gained interest recently with further studies showing acceptable outcomes in IPSS scores at 24-months' postintervention. Despite this, TURP results in significantly better (P ¼ 0.029) outcomes in IPSS scores and quality of life scores at 1-months' and 3-months' postprocedure. 38 Another large prospective series by Pisco et al 39 reported a 63% reduction in IPSS at 36-months' follow-up with PAE.
Complications of PAE are not insignificant and include failure of the procedure, dysuria, hematuria, hematospermia, rectal bleeding, and urinary retention. Although rare, risks of inadvertent embolization and untargeted ischemia of the bladder, corpus cavernosum, or anus do exist and pose a significant compromise to patient outcomes. A recent meta-analysis identified six cases of bladder ischemia. 37 More long-term data is necessary to define the safety and feasibility of PAE.
Rezum
Rezum (NxThera, Inc., Maple Grove, MN, USA) is a thermoablative strategy that relies on water vapor to deliver energy. This system allows convective thermal energy to travel through the interstitium of the transition zone of the prostate, disrupting cell membranes, and causing instant cell death and necrosis. The vapor is delivered transurethrally during cystoscopy, frequently performed under local anaesthetic in the outpatient setting. The Rezum system also works without creating a discernable thermal gradient, reducing the risk of injury to surrounding tissues by dissipated heat.
A recent multicenter RCT reviewed the outcomes of Rezum compared with controls and displayed significant results in the reduction of IPSS (P < 0.0001) with sustainable results of 50% or more at 12-months' follow-up. 40 Peak flow rates in this group were increased by 6.2 mL/s at 3 months and were sustained at 12 months. Rezum also provides a relatively low risk of compromising sexual function. 41 
Histotripsy
Histotripsy is a relatively modern application of high intensity ultrasound technology that is used to create negative pressure changes in tissue. This causes fluid in the tissues to vaporize and release highly energetic gaseous microbubbles that cause disruption to integral cellular structures ultimately leading to tissue destruction. The resulting tissues are homogenized and display a liquefied core of cytoplasm and cellular debris. 42 This technique has been used to create a cavitation effect in the prostate gland in a real time setting. Studies to date have been limited to canine models but have been promising in the cavitation effect resulting from histotripsy. 43 These models have also shown promise in preserving vital structures surrounding the prostate and of the prostatic urethra. Initiation of human pilot trials are on in progress and are sure to add valuable information to this experimental entity. 43 
44

Recommendations and summary
The rise in MIST procedures represents a paradigm shift in the treatment of BPH. The aim of achieving a personalized medicine approach has led to the use of these "middle-ground" therapies that lie between medical therapy and invasive surgical intervention. The MIST group is varied and continually growing in its range of options based on patient and pathological factors ( Table 1) . As the evidence for their utility is gathered, many of the MIST options remain experimental or without a robust evidence base. MIST should be used in a select patient group, particularly those that place importance on preserved sexual and continence function rather than urinary improvement. More mature data will help to identify the role of MIST in the evolving treatment pathway of BPH.
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